Total market value: 654.38+07.39 billion.

Senxuan Medicine, a holding subsidiary of the company, is the main manufacturer and supplier of ritonavir intermediates in China, and ritonavir is an important raw material for Huirui Xinguan oral specific medicine.

Second, Jianfeng Group 600668

Total market value: 7.68 billion

The sales volume of Caronic Anhydride produced by its subsidiary, Shanghai North Carolina, is relatively small. At present, North Carolina, Shanghai no longer holds the patent of "a new synthetic method of valerolactone, carrot acid, carrot anhydride and their key intermediates".

Third, Shu 300204

Total market value: 1, 31.300 million company's drug BDB 00 1 for COVID-19 is being promoted in an orderly manner in overseas multi-center clinics.

Four. Hanyu Pharmaceutical 300 199

Total market value: 654.38+09.29 billion. The company has carried out technical exchanges and cooperation with Institute of Microbiology, China Academy of Sciences on peptide COVID-19 drugs. The two parties intend to jointly develop novel coronavirus polypeptide nasal spray, and have completed the neutralization experiment on pseudovirus of COVID-19 Omicron mutant.

Five, Haizheng Pharmaceutical 600267

Total market value:19.57 billion fujifilm started the clinical trial of Avigan (Farpiravir) in the United States, and the company is the only manufacturer of Farpiravir in China.

VI. Yaben Chemistry 30026 1

Total market value: 26.32 billion companies develop and produce pharmaceutical intermediate carotene anhydride, with a monthly production scale of 20 tons; The customers of the company's carotene anhydride and its derivatives are mainly domestic customers and Indian customers, so it is uncertain whether the company's carotene anhydride and its derivatives are indirectly supplied to Pfizer.

7. Frontiers 68822 1

Total market value: FB200 1, a new anti-COVID-19 drug for injection of 9.084 billion company, has been clinically tested in the United States, and has been approved for clinical phase I bypass trial in China.

Since 2022, COVID-19 concept stocks have soared. The U.S. government will formally implement the COVID-19 Rapid Test Plan on June 5438+1October 65438+May. It is estimated that the monthly demand will reach 2.6 billion doses, involving more than10 billion US dollars. It is predicted that in the near future, the global demand for COVID-19 testing will remain at an all-time high.